Dr. Marleen Jansen studied Health Sciences at VU University Amsterdam and Maastricht University, and received her doctorate degree from Maastricht University, the Netherlands. She has been trained in implementation research, health technology assessment, and public health genomics. In January 2016 she successfully defended her thesis on “Implementing Genetic Tests – Infertility and Newborn Bloodspot Screening” at Maastricht University. Part of her PhD-research was carried out at the Office of Population Health Genomics Perth, Western Australia. Her PhD-project facilitated the development of an international network of screening experts.
The main goal in Dr. Jansen’s research is how to translate genetic information in a responsible way to maximize improved health outcomes. This resulted into several research projects, such as pharmacogenetics, value-based healthcare, and evidence-based policy making. Within the latter Dr. Jansen focusses on neonatal bloodspot screening by studying international perspectives on screening policy and implementation, and involvement in the expansion of the national screening program in the Netherlands.
Since 2018 Dr Jansen is employed by the Dutch National Institute for Public Health and the Environment (RIVM) Bilthoven. She joined the multidisciplinary group that is involved in the further expansion of the Dutch neonatal screening panel. In addition she leads a project aiming to standardise information material for prospective parents.